Immune-related adverse events with immune checkpoint blockade: a comprehensive review JM Michot, C Bigenwald, S Champiat, M Collins, F Carbonnel, ... European journal of cancer 54, 139-148, 2016 | 2147 | 2016 |
Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations DM Hyman, I Puzanov, V Subbiah, JE Faris, I Chau, JY Blay, J Wolf, ... New England Journal of Medicine 373 (8), 726-736, 2015 | 1914 | 2015 |
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up M Ducreux, AS Cuhna, C Caramella, A Hollebecque, P Burtin, D Goéré, ... Annals of oncology 26, v56-v68, 2015 | 1558 | 2015 |
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study GK Abou-Alfa, V Sahai, A Hollebecque, G Vaccaro, D Melisi, R Al-Rajabi, ... The Lancet Oncology 21 (5), 671-684, 2020 | 1287 | 2020 |
Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1 S Champiat, L Dercle, S Ammari, C Massard, A Hollebecque, ... Clinical Cancer Research 23 (8), 1920-1928, 2017 | 1238 | 2017 |
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study R Sun, EJ Limkin, M Vakalopoulou, L Dercle, S Champiat, SR Han, ... The Lancet Oncology 19 (9), 1180-1191, 2018 | 989 | 2018 |
The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids A Louvet, S Naveau, M Abdelnour, MJ Ramond, E Diaz, L Fartoux, ... Hepatology 45 (6), 1348-1354, 2007 | 861 | 2007 |
High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial C Massard, S Michiels, C Ferté, MC Le Deley, L Lacroix, A Hollebecque, ... Cancer discovery 7 (6), 586-595, 2017 | 684 | 2017 |
Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease P Mathurin, A Hollebecque, L Arnalsteen, D Buob, E Leteurtre, R Caiazzo, ... Gastroenterology 137 (2), 532-540, 2009 | 588 | 2009 |
Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer RB Corcoran, T André, CE Atreya, JHM Schellens, T Yoshino, JC Bendell, ... Cancer discovery 8 (4), 428-443, 2018 | 561 | 2018 |
Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE … MA Shah, T Kojima, D Hochhauser, P Enzinger, J Raimbourg, ... JAMA oncology 5 (4), 546-550, 2019 | 452 | 2019 |
Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor A Louvet, F Wartel, H Castel, S Dharancy, A Hollebecque, ... Gastroenterology 137 (2), 541-548, 2009 | 427 | 2009 |
Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised … E Garin, L Tselikas, B Guiu, J Chalaye, J Edeline, T de Baere, E Assenat, ... The lancet Gastroenterology & hepatology 6 (1), 17-29, 2021 | 424 | 2021 |
Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II CheckMate 358 trial RW Naumann, A Hollebecque, T Meyer, MJ Devlin, A Oaknin, J Kerger, ... Journal of Clinical Oncology 37 (31), 2825-2834, 2019 | 362 | 2019 |
Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer A Simonaggio, JM Michot, AL Voisin, J Le Pavec, M Collins, A Lallart, ... JAMA oncology 5 (9), 1310-1317, 2019 | 326 | 2019 |
BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study T Kaley, M Touat, V Subbiah, A Hollebecque, J Rodon, AC Lockhart, ... Journal of Clinical Oncology 36 (35), 3477-3484, 2018 | 314 | 2018 |
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma L Goyal, F Meric-Bernstam, A Hollebecque, JW Valle, C Morizane, ... New England Journal of Medicine 388 (3), 228-239, 2023 | 259 | 2023 |
Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment R Belkhir, S Le Burel, L Dunogeant, A Marabelle, A Hollebecque, B Besse, ... Annals of the rheumatic diseases 76 (10), 1747-1750, 2017 | 242 | 2017 |
Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer JH Strickler, H Satake, TJ George, R Yaeger, A Hollebecque, ... New England journal of medicine 388 (1), 33-43, 2023 | 223 | 2023 |
Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2–dependent and other solid tumors L Gandhi, R Bahleda, SM Tolaney, EL Kwak, JM Cleary, SS Pandya, ... Journal of Clinical Oncology 32 (2), 68-75, 2014 | 218 | 2014 |